Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM326 for chronic rhinosinusitis with nasal polyps (CRSwNP)
CTR20260394Phase 3Active
- Sponsor
- Keymed Biosciences
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CM326 in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Keymed Biosciences. Started Feb 2026; status: active.
02
Drugs
CM326
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on CTR20260394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260394.